13F HOLDINGS REPORT
Wildcat Capital Management, LLC
Quarter ended Q4 2024 · Filed January 29, 2025 · Accession 0001999371-25-000847
Total Value
$252.7M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | FRONTIER GROUP HLDGS INC | ULCC | 28,061,351 | $199.5M | 78.95% |
| 2 | RLX TECHNOLOGY INC | RLX | 18,046,195 | $39.0M | 15.42% |
| 3 | ALLOGENE THERAPEUTICS INC | ALLO | 2,920,787 | $6.2M | 2.46% |
| 4 | UROGEN PHARMA LTD | URGN | 495,606 | $5.3M | 2.09% |
| 5 | KRONOS BIO INC | 50107A104 | 1,297,959 | $1.2M | 0.49% |
| 6 | GITLAB INC | GTLB | 11,399 | $642,334 | 0.25% |
| 7 | PROCORE TECHNOLOGIES INC | PCOR | 8,095 | $606,558 | 0.24% |
| 8 | SILEXION THERAPEUTICS CORP | SLXNW | 113,428 | $227,990 | 0.09% |